The main dangers of osteoporosis drugs are uncommon but real: osteonecrosis of the jaw and atypical femoral fractures with long-term antiresorptives, rebound fractures when denosumab is stopped abruptly, blood clots with raloxifene, and cardiovascular warnings with romosozumab. For most people at high fracture risk, the benefit of preventing a hip or spine fracture clearly outweighs these risks. Safe prescribing comes down to choosing the right drug, screening before starting, and planning how and when treatment will end.
Why Osteoporosis Drugs Are Worth the Risk for Most Patients
Osteoporosis is a loss of bone mass and bone architecture that leaves the skeleton fragile. It is silent until a fracture happens, most often at the hip, spine, or wrist. A hip fracture in an older adult frequently means lost independence, and it carries a real risk of death in the following year.
As a clinician working in hematology and bone medicine, I see the dangers of osteoporosis drugs discussed far more often than the dangers of untreated osteoporosis. That imbalance leads some patients to refuse treatment they need. The goal is not to avoid these medicines but to use them wisely.
Treatment is usually offered when a DEXA scan shows a T-score of −2.5 or lower, when someone has had a fragility fracture, or when a tool such as FRAX estimates a high 10-year fracture risk.
Side Effects and Dangers by Drug Class
Osteoporosis medicines fall into two broad groups. Antiresorptive drugs slow the osteoclasts that break bone down. Anabolic drugs stimulate osteoblasts to build new bone. Each group has its own safety profile.
| Drug class | Examples | Common side effects | Rare but serious risks |
|---|---|---|---|
| Oral bisphosphonates | Alendronate, risedronate, ibandronate | Heartburn, esophageal irritation, stomach upset | Osteonecrosis of the jaw, atypical femoral fracture |
| IV bisphosphonate | Zoledronic acid | Flu-like reaction after the first infusion | Kidney injury, hypocalcemia, jaw osteonecrosis, atypical fracture |
| RANK ligand inhibitor | Denosumab | Back and limb pain, skin reactions | Severe hypocalcemia, rebound vertebral fractures if stopped abruptly |
| SERM | Raloxifene | Hot flashes, leg cramps | Deep vein thrombosis, pulmonary embolism, fatal stroke in high-risk women |
| PTH analogs | Teriparatide, abaloparatide | Nausea, dizziness on standing, leg cramps | Raised blood calcium; osteosarcoma seen in rat studies |
| Sclerostin antibody | Romosozumab | Joint pain, headache, injection-site reactions | Boxed warning for heart attack, stroke, and cardiovascular death |
The Most Discussed Dangers in Detail
Osteonecrosis of the jaw (ONJ)
Osteonecrosis of the jaw is exposed, non-healing jawbone that persists for more than eight weeks. At the doses used for osteoporosis it is rare. The risk is much higher with the frequent, high doses given to cancer patients with bone metastases.
Risk rises with invasive dental work such as extractions, poor oral hygiene, smoking, glucocorticoids, and longer treatment. A dental check before starting and good oral care during treatment are the best protection.
Atypical femoral fractures (AFF)
These are unusual stress fractures of the thigh bone shaft that occur with little or no trauma. They are linked mainly to long-term bisphosphonate or denosumab use. Many patients notice a dull ache in the thigh or groin for weeks beforehand, which should prompt an X-ray of both femurs.
Rebound fractures after stopping denosumab
Denosumab’s effect wears off quickly. If injections are delayed or stopped without follow-on treatment, bone turnover surges and multiple vertebral fractures can occur. Denosumab should not be stopped without a plan, usually a bisphosphonate, to lock in the gains.
Cardiovascular and clotting risks
Romosozumab carries a boxed warning and should not be started within a year of a heart attack or stroke. Raloxifene raises the risk of venous blood clots and is avoided in people with a history of thrombosis or prolonged immobility.
Screening Before Starting Treatment
Many adverse effects can be prevented by checking a few things first. Before prescribing, I review:
- Calcium and vitamin D: low levels must be corrected first, or hypocalcemia becomes more likely, especially with denosumab and zoledronic acid.
- Kidney function: most bisphosphonates are avoided when creatinine clearance falls below roughly 30–35 mL/min.
- Esophageal health: oral bisphosphonates are avoided in people who cannot sit upright for 30 minutes or who have esophageal disorders.
- Dental status: planned extractions or implants are ideally completed before starting an antiresorptive.
- Cardiovascular and clotting history: this shapes whether romosozumab or raloxifene is appropriate.
- Secondary causes of bone loss: conditions such as myeloma, hyperparathyroidism, or celiac disease should be excluded.
Reducing Risk During Long-Term Treatment
Taking oral bisphosphonates correctly makes a big difference. They should be swallowed with a full glass of plain water on an empty stomach, and the patient should stay upright and avoid food for at least 30 minutes.
Bisphosphonates remain stored in bone, so lower-risk patients may take a drug holiday after about three to five years. The fracture risk is then reassessed, and treatment restarts if it rises. Denosumab is the exception, because stopping it without a follow-on drug is unsafe.
Anabolic agents have fixed courses. Romosozumab is given for 12 months, and PTH analogs are typically used for up to two years. Each should be followed by an antiresorptive so the new bone is not lost. Managing fracture pain alongside drug therapy is covered in our article on osteoporosis treatment and pain management, and the wider picture is in our osteoporosis guide.
When to See a Doctor
Contact your doctor promptly if you are taking an osteoporosis medicine and notice any of the following:
- New thigh or groin pain, especially if it is dull and persistent
- Jaw pain, swelling, loose teeth, or exposed bone in the mouth
- Painful swallowing or new chest pain after oral tablets
- Muscle cramps, tingling around the mouth, or spasms, which can signal low calcium
- Leg swelling, chest pain, or sudden breathlessness
- A missed or overdue denosumab injection
Frequently Asked Questions
Are osteoporosis drugs more dangerous than osteoporosis itself?
For people at high fracture risk, generally no. Serious side effects such as jaw osteonecrosis and atypical fractures are rare, while hip and spine fractures are common and disabling in untreated osteoporosis. The balance is less clear for people at low risk, which is why treatment decisions are individualized.
Can I stop denosumab if I am worried about side effects?
Not on your own. Stopping denosumab abruptly can trigger a rapid loss of bone and multiple spinal fractures. Your doctor can plan a safe transition, usually to a bisphosphonate.
Do I need to see a dentist before starting treatment?
It is sensible, especially before bisphosphonates or denosumab. Completing extractions or other invasive work first lowers the already small risk of jaw osteonecrosis. Tell your dentist which bone medicine you take.
What is a bisphosphonate drug holiday?
It is a planned break after several years of bisphosphonate therapy in people whose fracture risk has become lower. The drug stays in bone and keeps working for a while, and the break reduces exposure to long-term risks. Your doctor will reassess bone density and risk during the holiday.
